炎症性肠病患者从生物类似药维持治疗转换为Remicade的结局
该研究为前瞻性观察性研究,纳入匈牙利174例接受生物类似药CT-P13维持治疗的炎症性肠病患者(136例克罗恩病、38例溃疡性结肠炎),2017年9月因报销政策转换为Remicade。转换后第16周和第24周临床缓解率、谷浓度及抗药抗体阳性率均无显著变化,未发现新的安全性信号。
要点
- 从CT-P13转换为Remicade后,克罗恩病和溃疡性结肠炎患者临床缓解率无显著差异。
- 转换前后英夫利西单抗平均谷浓度及抗药抗体阳性率均无显著变化。
- 随访至第24周共发生4例输注反应,未发现新的安全性信号。
核心结论
- 从生物类似药转换为Remicade后,患者临床缓解率、谷浓度及抗药抗体无显著变化,未发现新的安全性信号。
研究设计与样本
- 前瞻性观察性研究,纳入174例未选择的连续炎症性肠病患者(136例克罗恩病,38例溃疡性结肠炎),均接受生物类似药CT-P13维持治疗。
- 2017年9月因报销政策将患者从CT-P13转换为Remicade,其中8%(n=14)既往曾暴露于原研药Remicade。
- 在基线(转换时)及转换后第16周和第24周收集临床和生化信息。
主要发现
- 转换前第8周临床缓解比例:克罗恩病82.5%,溃疡性结肠炎82.9%;基线:克罗恩病80.6%,溃疡性结肠炎81.6%;第16周:克罗恩病77.5%,溃疡性结肠炎83.7%;第24周:克罗恩病76.3%,溃疡性结肠炎84.9%;组间比较克罗恩病P=0.60,溃疡性结肠炎P=0.98。
- 所有患者平均英夫利西单抗血清谷浓度:基线5.33±4.70 μg/mL,第16周5.69±4.94 μg/mL(P=0.71)。
- 抗药抗体阳性率:基线16.2%,第16周16.9%(P=0.87)。
- 截至第24周随访共发生4例输注反应。
- 既往暴露于Remicade与未暴露患者在结局、谷浓度或抗药抗体水平上无差异。
关键数值与推荐
- 临床缓解定义:克罗恩病疾病活动指数<150分或无瘘管引流,或溃疡性结肠炎部分Mayo评分<3分。
- 在基线及第16周测量血清药物谷浓度和抗药抗体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is evidence that it is safe and effective for patients with inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original infliximab drug to a biosimilar, but little is known about outcomes of reverse switches and/or multiple switches. We aimed to evaluate the effects of a reverse switch (from a biosimilar to Remicade) in a real-life cohort. METHODS: We performed a prospective observational study of 174 unselected and consecutive patients with IBD (136 with Crohn's disease [CD] and 38 with ulcerative colitis [UC]) who received maintenance therapy with the biosimilar in Hungary. In September 2017, patients were switched from the biosimilar (CT-P13) to Remicade, due to reimbursement policies. In our cohort, 8% (n = 14) patients had been previously exposed to the originator Remicade. We collected clinical and biochemical information from patients at baseline (time of the switch) and 16 and 24 weeks thereafter. Clinical remission was defined as a Crohn's disease activity index <150 points or no fistula drainage, or a partial Mayo score <3 points for patients with UC. Serum drug trough levels and anti-drug antibodies were measured at baseline and week 16. RESULTS: There was no significant difference in the proportion of patients in clinical remission at week 8 before the switch (82.5% with CD and 82.9% with UC), at baseline (80.6% with CD and 81.6% with UC), at week 16 (77.5% with CD and 83.7% with UC), or at week 24 (CD 76.3% with CD and 84.9% with UC) (P = .60 among groups for patients with CD and P = .98 among groups for patients with UC). For all patients, mean serum trough levels of infliximab were 5.33 ± 4.70 μg/mL at baseline and 5.69 ± 4.94 μg/mL at week 16 (P = .71); we did not find significant differences in prevalence of anti-drug antibody at baseline (16.2%) compared with week 16 (16.9%) (P = .87). Four infusion reactions occurred, until week 24 of follow up. There was no difference in outcomes or trough or antidrug antibody levels between patients with or without previous exposure to Remicade. CONCLUSIONS: We collected data from a real-life cohort of patients with CD or UC who were switched from maintenance therapy with a biosimilar to Remicade or were treated with only Remicade. No significant changes were observed in remission, trough levels, or antidrug antibodies in patients switched from the biosimilar to Remicade. No new safety signals were detected.
引用
- Ilias A, Szanto K, Gonczi L, et al. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade. Clin Gastroenterol Hepatol. 2019. PMID: 30630103. doi:10.1016/j.cgh.2018.12.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。